Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 31 July 2013 | By Louise Zornoza,
Australia's Therapeutic Goods Administration (TGA) has issued guidance on the evaluation of biosimilar products, which identifies the data necessary to support applications for the registration of biosimilars and clarifies the scientific and regulatory principles used by the TGA to evaluate applications.
TGA notes that although most biosimilars contain biotechnology-derived proteins as the active substance(s), the guidance also covers biosimilars consisting of vaccines and monoclonal antibodies and polysaccharides, such as low molecular weight heparins. The guidance also underscores that while biosimilars have some conceptual parallels with generic versions of medicines containing chemically-derived small molecules as the active substances, the complexity and microheterogeneity of biotechnology products means that the principles relevant to the evaluation and use of generics cannot be simply extrapolated to biosimilars.
The new guidance also addresses comparability studies for evaluating biosimilars, with sections on physicochemical properties, biological activity, content, purity and impurity profile, glycosylation (if applicable) and immunochemistry (if applicable e.g. monoclonal antibodies); post-registration regulation and pharmacovigilance; biosimilar naming convention; and labeling and product information.
Read all Breaking News from RegLink
Tags: biosimilar, australia, Biosimilars
Regulatory Focus newsletters
All the biggest regulatory news and happenings.